Health Condition 1: null- Sinus Tachycardia
Conditions
Interventions
Intervention1: Ivabradine: 7.5 mg, Per-oral or via NG Tube, 2 doses at 12 hours apart
Control Intervention1: Pantoprazole: 40 mg, Per-oral or via NG Tube, 2 doses at 12 hours apart.
Sponsors
Fluid Research Grant Christian Medical CollegeVellore Tamilnadu
Eligibility
Inclusion criteria
Inclusion criteria: a)Aged above 18 years b)Sinus rhythm with heart rate above 120 bpm c) 24 hours of admission to the ICU with a diagnosis of shock. d)In case of patients admitted with Organophosphorus poisoning, they should have been off atropine for at least 48 hours.
Exclusion criteria
Exclusion criteria: ICU Physician assessment Sick sinus syndrome Sinu-atrial block Pacemaker-dependency 3rd degree AV block Ongoing fluid/volume loss On concomitant use of potent CYP3A4 inhibitors: Azole antifungals (ketoconazole, itraconazole), Clarithromycin , erythromycin, josamycin, telithromycin, HIV protease inhibitors (nelfinavir, ritonavir)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Comparison of the mean heart rate between the treatment and control group 24 hours after the initiation of the treatment.Timepoint: 24 hours | — |
Secondary
| Measure | Time frame |
|---|---|
| Hemodynamic parameters up to 24 hrs. Blood pressure and Mean Arterial Pressure (mm of Hg) Urine output (ml/ hour) Estimated Glomerular Filtration Rate (eGFR) Blood lactate levels P:F ratio Duration of ventilation days MortalityTimepoint: 24 hours | — |
Countries
India
Contacts
Public ContactDr Shubhanker Mitra
Outcome results
None listed